Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (52)

2024

  1. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  3. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies

    The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 859-883

  4. Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis

    Hepatology, Vol. 79, Núm. 3, pp. 624-635

  5. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  6. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. AEEH «Consensus about detection and referral of hidden prevalent liver diseases»

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 3, pp. 236-247

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 1, pp. 114-122

  5. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  6. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 79-92

2022

  1. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2021

  1. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 589-599

  2. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data

    Gastroenterology, Vol. 160, Núm. 1, pp. 193-205.e10

  3. Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature

    Hepatology Communications, Vol. 5, Núm. 2, pp. 309-322

  4. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Journal of Hepatology, Vol. 74, Núm. 5, pp. 1097-1108

  5. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    JHEP Reports, Vol. 3, Núm. 6

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Journal of Hepatology, Vol. 73, Núm. 5, pp. 1082-1091